Foscenvivint
Cirrhosis Of Liver
Kiminori Kimura, MDSmall moleculePhase 2Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
133 Active assets in the Cirrhosis Of Liver cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Veruprevir AbbVie | Phase 3 | A |
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) General Hospital of Shenyang Military Region | Phase 4 | BBB |
Tolvaptan Institute of Liver and Biliary Sciences, India | Phase 4 | BBB |
Normal Human Serum Albumin King George's Medical University | Phase 4 | BBB |
Ribavirin Peking University People's Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Foscenvivint is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →